Sun Helps Prevent NHL?!

In the International Journal of Cancer, December 10th issue, Australian researchers report sun exposure apparently has a protective effect against the development non-Hodgkin's lymphoma (NHL).



Dr. Anne Kricker, of the University of Sydney, and colleagues investigated the possibility that high sun exposure is associated with an increased risk of NHL -- and found the opposite!



The risk of NHL decreased with increasing hours of sun exposure. With the highest exposures, the odds of having NHL decreased by 35 percent compared with the lowest exposure level.



One effect of sunlight is to stimulate the body's production of vitamin D. The researchers say that "increasing evidence that vitamin D may protect against cancer makes ultraviolet-mediated synthesis of vitamin D a plausible mechanism whereby sun exposure might protect against NHL."



Now you might be at risk for skin cancer so don't overdo it!

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap